vs
Side-by-side financial comparison of Broadstone Net Lease, Inc. (BNL) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $121.4M, roughly 1.4× Broadstone Net Lease, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 11.7%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.1%).
Broadstone Net Lease, Inc. is a real estate investment trust (REIT) that acquires, owns, and manages a diversified portfolio of single-tenant commercial real estate assets across the United States. Its portfolio covers key segments including industrial facilities, healthcare properties, retail locations, and office spaces, all leased to tenants under long-term net lease agreements.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BNL vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $121.4M | $168.4M |
| Net Profit | $46.4M | — |
| Gross Margin | — | — |
| Operating Margin | 52.2% | 50.6% |
| Net Margin | 38.2% | — |
| Revenue YoY | 11.7% | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.24 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $121.4M | — | ||
| Q4 25 | $118.3M | $168.4M | ||
| Q3 25 | $114.2M | $87.3M | ||
| Q2 25 | $113.0M | $82.4M | ||
| Q1 25 | $108.7M | $65.0M | ||
| Q4 24 | $112.1M | $69.1M | ||
| Q3 24 | $108.4M | $51.6M | ||
| Q2 24 | $105.9M | $73.8M |
| Q1 26 | $46.4M | — | ||
| Q4 25 | $33.1M | — | ||
| Q3 25 | $26.5M | $-31.3M | ||
| Q2 25 | $20.2M | $-12.7M | ||
| Q1 25 | $16.7M | $-40.5M | ||
| Q4 24 | $26.4M | — | ||
| Q3 24 | $35.6M | $-29.5M | ||
| Q2 24 | $35.3M | $-61.9M |
| Q1 26 | 52.2% | — | ||
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | — | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | — | -31.0% | ||
| Q2 24 | — | 3.5% |
| Q1 26 | 38.2% | — | ||
| Q4 25 | 28.0% | — | ||
| Q3 25 | 23.2% | -35.9% | ||
| Q2 25 | 17.8% | -15.4% | ||
| Q1 25 | 15.4% | -62.2% | ||
| Q4 24 | 23.5% | — | ||
| Q3 24 | 32.8% | -57.2% | ||
| Q2 24 | 33.4% | -83.9% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.17 | $0.32 | ||
| Q3 25 | $0.14 | $-0.16 | ||
| Q2 25 | $0.10 | $-0.06 | ||
| Q1 25 | $0.09 | $-0.21 | ||
| Q4 24 | $0.13 | $-0.14 | ||
| Q3 24 | $0.19 | $-0.15 | ||
| Q2 24 | $0.19 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.3M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.0B | $-302.0M |
| Total Assets | $5.8B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.3M | — | ||
| Q4 25 | $30.5M | $167.9M | ||
| Q3 25 | $82.0M | $92.4M | ||
| Q2 25 | $20.8M | $86.1M | ||
| Q1 25 | $9.6M | $114.6M | ||
| Q4 24 | $14.8M | $144.8M | ||
| Q3 24 | $9.0M | $144.7M | ||
| Q2 24 | $18.3M | $189.3M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.9B | — |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.9B | $-302.0M | ||
| Q3 25 | $2.9B | $-451.4M | ||
| Q2 25 | $2.9B | $-433.5M | ||
| Q1 25 | $2.9B | $-426.2M | ||
| Q4 24 | $3.0B | $-388.7M | ||
| Q3 24 | $3.0B | $-370.2M | ||
| Q2 24 | $3.1B | $-344.2M |
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.7B | $465.9M | ||
| Q3 25 | $5.5B | $364.0M | ||
| Q2 25 | $5.3B | $347.1M | ||
| Q1 25 | $5.2B | $324.0M | ||
| Q4 24 | $5.2B | $343.8M | ||
| Q3 24 | $5.3B | $314.1M | ||
| Q2 24 | $5.3B | $352.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.87× | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.68× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $299.5M | $45.2M | ||
| Q3 25 | $64.2M | $-4.3M | ||
| Q2 25 | $79.3M | $-31.4M | ||
| Q1 25 | $71.5M | $-22.6M | ||
| Q4 24 | $276.3M | $-35.0M | ||
| Q3 24 | $67.3M | $-35.3M | ||
| Q2 24 | $74.2M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | $269.8M | — | ||
| Q3 25 | $58.0M | — | ||
| Q2 25 | $76.7M | — | ||
| Q1 25 | $57.1M | — | ||
| Q4 24 | $259.5M | — | ||
| Q3 24 | $60.3M | $-35.5M | ||
| Q2 24 | $74.0M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 228.1% | — | ||
| Q3 25 | 50.8% | — | ||
| Q2 25 | 67.9% | — | ||
| Q1 25 | 52.5% | — | ||
| Q4 24 | 231.4% | — | ||
| Q3 24 | 55.6% | -68.7% | ||
| Q2 24 | 69.9% | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | 25.1% | 0.0% | ||
| Q3 25 | 5.4% | 0.0% | ||
| Q2 25 | 2.3% | 0.0% | ||
| Q1 25 | 13.2% | 0.0% | ||
| Q4 24 | 15.0% | 0.0% | ||
| Q3 24 | 6.5% | 0.3% | ||
| Q2 24 | 0.2% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 9.04× | — | ||
| Q3 25 | 2.43× | — | ||
| Q2 25 | 3.93× | — | ||
| Q1 25 | 4.27× | — | ||
| Q4 24 | 10.47× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 2.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNL
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
